Adiponectin and atherosclerosis risk factors in African hemodialysis patients: A population at low risk for atherosclerotic cardiovascular disease

Hemodialysis International

Volumn 16, Issue 1, 2012, Pages 59-68

  Amira, Oluwatoyin C ^a   Naicker, Saraladevi ^a   Manga, Pravin ^a   Sliwa, Karen ^a   Mia, Alamgir ^a   Raal, Frederick ^a   Crowther, Nigel John ^a   Immelman, Ronald A ^a   Olorunju, Steve ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Adiponectin; Atherosclerosis; Cardiovascular risk factors; Hemodialysis

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; LIPID; TRIACYLGLYCEROL;

ADIPOCYTE; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; B SCAN; BLOOD PRESSURE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROTEIN SECRETION; RACE DIFFERENCE; RISK FACTOR; SEX RATIO; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; ATHEROSCLEROSIS; CHOLESTEROL, HDL; ECHOCARDIOGRAPHY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 84856400804     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00622.x     Document Type: Article

References (34)

1. Foley RN, Parfrey PS, Sarnak MJ. Cardiovascular disease in chronic renal disease: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32:S112-S119.
2. Linder A, Charra B, Sherrard DJ, etal. Accelerated atherosclerosis in prolonged maintenance haemodialysis. N Engl J Med. 1974; 290:697-701.
3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis. 2000; 35:S117-S131.
4. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit. 2003; 9:55-61.
5. Zoccali C, Mallamaci F, Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and in disease: Focus on end-stage renal disease. Kidney Int. 2003; 63:S65-S68.
6. Zoccali C, Mallamaci F, Tripepi G, etal. Adiponectin, metabolic risk factors and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13:134-141.
7. Hotta K, Funahashi T, Arita Y, etal. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20:1595-1599.
8. Kumada M, Kihara S, Sumitsuji S, etal. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23:85-89.
9. Ignacy W, Chudek J, Adamczak M, etal. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease-A follow-up study. Nephron Clin Pract. 2005; 101:18-24.
10. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chim Acta. 1972; 18:499-502.
11. Bots ML, Evans GW, Riley WA, etal. Carotid intima-media thickness measurements in intervention studies: Design options, progression rates, and sample size considerations: A point of view. Stroke. 2003; 34:2985-2994.
12. Simon A, Gariepy J, Chironi G, etal. Intima-media thickness: A new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002; 20:159-169.
13. Kaddoura S, ed. Echo Made Easy. London: Churchill Livingstone. 2002.
14. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation. 1977; 55:613-618.
15. Tentolouris N, Doulgerakis D, Moyssakis I, etal. Plasma adiponectin concentrations in patients with chronic renal failure: Relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res. 2004; 36:721-727.
16. Huang JW, Yen CJ, Chiang HW, etal. Adiponectin in peritoneal dialysis patients: A comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis. 2005; 43:1047-1055.
17. Lee CT, Lee CH, Su Y, etal. The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs. 2004; 27:835-841.
18. Shoji T, Shinohara K, Hatsuda S, etal. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism. 2005; 54:330-334.
19. Diez JJ, Iglesias P, Fernandez-Reyes MJ, etal. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf). 2005; 62:242-249.
20. Guebre-Egziabher F, Bernhard J, Funahashi T, etal. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant. 2005; 20:129-134.
21. Chitalia N, Raja RB, Bhandara T, etal. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol. 2010; 23:77-84.
22. Adamczak M, Rzepka E, Chudek J, Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxf). 2005; 62:114-118.
23. Chudek J, Adamczak M, Karkoszka H, etal. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc. 2003; 35:2186-2189.
24. Nakamura Y, Shimada K, Fukuda D, etal. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004; 90:528-533.
25. Kalantar-Zadeh K, Block G, Humphreys MH, etal. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003; 63:793-808.
26. Ouchi N, Kihara S, Funahashi T, etal. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003; 107:671-674.
27. Ouchi N, Kihara S, Arita Y, etal. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102:1296-1301.
28. Komaba H, Igaki N, Goto S, etal. Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus. Nephron Clin Pract. 2007; 107:c103-c108.
29. Ayerden Ebinç F, Ebinç H, Derici U, etal. The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients. J Nephrol. 2009; 22:216-223.
30. Wang AY, Wang M, Woo J, etal. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int. 2002; 62:639-647.
31. Redón J, Cea-Calvo L, Lozano JV, etal. Kidney function and cardiovascular disease in the hypertensive population: The ERIC-HTA study. J Hypertens. 2006; 24:663-669.
32. Pääkkö T, Ukkola O, Ikäheimo M, etal. Plasma adiponectin levels are associated with left ventricular hypertrophy in a random sample of middle-aged subjects. Ann Med. 2010; 42:131-137.
33. McManus DD, Lyass A, Ingelsson E, etal. Relations of circulating resistin and adiponectin and cardiac structure and function: The Framingham Offspring Study. Obesity. 2011; doi: 10.1038/oby.2011.32. Epub ahead of print.
34. Sattar N, Wannamethee G, Sarwar N, etal. Adiponectin and coronary heart disease. A prospective study and meta-analysis. Circulation. 2006; 106:623-629.